On April 2, 2026, President Trump issued a proclamation imposing tariffs up to 100 percent on patented pharmaceuticals and active pharmaceutical ingredients (APIs) under Section 232 of the Trade Expansion Act of 1962. The tariffs take effect July 31, 2026 (for major manufacturers) and September 29, 2026 (for others). For pharmaceutical and biotech boards, this represents an immediate and material decision window. Companies can reduce exposure from 100 percent to 20 percent through onshoring plans, or to zero percent through a combination of onshoring and Most Favored Nation pricing agreements with the Secretary of Health and Human Services. The governance imperative is clear: boards must understand the financial exposure, the compliance obligations that accompany tariff mitigation strategies, and the strategic trade-offs between operational restructuring and pricing constraints.
This is not a trade policy announcement. This is a board-level action item with three distinct decision pathways, external reporting requirements, and downstream enforcement mechanisms that include retroactive tariff imposition for non-compliance. Boards of pharmaceutical and biotech companies must evaluate both the tariff exposure on their patent-protected product portfolios and the governance costs of pursuing mitigation pathways. The decision window is compressed: the effective date is less than one hundred days away, onshoring plans must be approved by the Secretary of Commerce before tariffs hit, and MFN agreements must be negotiated with HHS before the tariffs take effect.
What the April 2 Proclamation Actually Does
The proclamation imposes a 100 percent ad valorem tariff on patented pharmaceuticals listed in the FDA’s Orange Book or Purple Book, as well as their active pharmaceutical ingredients. The definition is specific: only patent-protected products are subject to the 100 percent rate. Generic pharmaceuticals, biosimilar products, and orphan drugs (products for rare diseases) are excluded. This distinction matters for portfolio planning because companies with diversified product portfolios face layered tariff exposure.
The tariff applies to all imports of covered products, regardless of origin country. However, the proclamation establishes country-specific preferential rates for major trading partners. The United Kingdom qualifies for a 10 percent rate (with the possibility of reduction to 0 percent pending U.S.-UK pricing negotiations). The European Union, Japan, South Korea, Switzerland, and Liechtenstein receive a 15 percent rate. China and other non-preferential countries face the full 100 percent rate.
For companies operating multinational supply chains or considering geographic restructuring, these country-specific rates create an additional strategic layer. A manufacturer sourcing APIs from India or China faces 100 percent tariffs, while sourcing from Switzerland incurs 15 percent tariffs. This differential creates immediate pressure to evaluate supply chain restructuring or onshoring strategies.
Three Pathways to Reduce Tariff Exposure
The proclamation provides three explicit mechanisms for tariff reduction. First, companies with a Secretary of Commerce-approved plan to transition production to the United States qualify for a 20 percent tariff rate. This rate applies to both the patent-protected finished product and the associated APIs. The onshoring commitment is not permanent: the 20 percent rate is set to escalate to 100 percent on April 2, 2030. Companies have a four-year window to complete onshoring commitments and permanently avoid the 100 percent tariff through operational relocation.
Second, companies that enter into MFN pharmaceutical pricing agreements with the Secretary of Health and Human Services can achieve a zero percent tariff rate until January 20, 2029. As of April 2026, the Trump administration has already secured agreements with fourteen companies. These agreements commit manufacturers to offer “most favored nation” pricing—matching the lowest prices they charge in other developed countries—for Medicaid and cash-paying customers. For companies already participating in MFN agreements, tariff exposure is zero. For companies considering entry, the quid pro quo is pricing constraint rather than operational restructuring.
Third, companies with both an approved onshoring plan and an MFN pricing agreement receive a zero percent tariff rate through January 20, 2029. This dual-pathway strategy preserves the tariff benefit while demonstrating commitment to manufacturing relocation. However, the onshoring commitment carries governance obligations that extend beyond procurement decisions.
The Board-Level Decision Window
The effective date of the tariffs is imminent. Tariffs apply to all entries on or after July 31, 2026 (Annex III companies, largely multinational pharma) and September 29, 2026 (smaller manufacturers and importers). This gives companies fewer than four months to prepare and, more critically, fewer than four months to submit onshoring plans for Commerce Department approval. Once tariffs take effect without an approved plan, a company faces 100 percent tariffs on all covered products until a plan is approved retroactively.
Boards must direct immediate action on portfolio mapping and financial exposure analysis. The critical question is not whether tariffs will take effect but how much of the company’s revenue-generating portfolio faces exposure. Patent-protected products with significant U.S. market demand carry the highest tariff impact. A blockbuster drug generating $500 million in annual U.S. revenue, if sourced from a non-preferential country, faces an additional $500 million in tariff liability per year at 100 percent. The financial materiality of this exposure justifies C-suite involvement and governance-level deliberation.
Companies pursuing the onshoring pathway must submit detailed plans to the Secretary of Commerce, who will publish qualifying criteria in the Federal Register. Until those criteria are published, companies cannot build plans to specification. This creates a governance risk: companies must begin planning without final regulatory guidance. Boards should direct legal and operational teams to develop preliminary plans based on the most stringent expectations and then refine once Commerce publishes the criteria.
Companies pursuing the MFN pathway must negotiate directly with HHS. The administration has signaled that the negotiations are competitive: companies that move quickly gain favorable agreements, while delayed movers face extended tariff exposure. Boards should authorize negotiation teams to engage HHS immediately and establish internal decision criteria for acceptable pricing constraints.
The Governance Imperative: Compliance and Monitoring
Both pathways carry ongoing compliance obligations that extend far beyond the initial strategic decision. Companies with approved onshoring plans must submit periodic progress reports to the Secretary of Commerce documenting progress toward manufacturing relocation milestones. The proclamation explicitly authorizes the Secretary to require external auditing of these progress reports. This creates a new external reporting obligation that boards have not historically managed in this form.
The enforcement mechanism is material. The Secretary has authority to reimpose tariffs—both prospectively and retroactively—against companies that fail to fulfill onshoring commitments or that violate the terms of MFN pricing agreements. The proclamation specifically references cases of fraud or deliberate misrepresentation. A company that submits an onshoring plan documenting commitments it later fails to meet, or that achieves MFN tariff reduction through pricing agreement but then allegedly violates agreement terms, faces not only prospective tariff imposition but also retroactive tariff assessment dating to the effective date of the original tariff relief.
This backward-looking enforcement creates contingent liability exposure that affects both financial statement accounting and risk disclosure. Boards should require that legal and finance teams model the retroactive tariff liability scenario and establish reserves or disclosure language in 10-K filings if the exposure is material.
The Extended Timeline and Future Regulatory Action
The proclamation contains a forward-looking directive to the Commerce Department. Within one year of the proclamation, Commerce must advise the President whether circumstances indicate a need to extend Section 232 tariffs to generic pharmaceuticals and associated ingredients. As of April 2026, generic drugs and biosimilars are excluded from tariff exposure. If Commerce recommends extending tariffs to generics, the President may issue a revised proclamation. Companies with significant generic or biosimilar portfolios should monitor this contingency closely and assume that tariff exposure could expand beyond patent-protected products within twelve months.
Additionally, the Secretary of Commerce and HHS are directed to pursue negotiations to address the alleged national security threat. The administration must update the President on negotiation progress within 90 days and must complete agreement negotiations within 180 days. If negotiations fail or if agreements are deemed ineffective, the President may take additional action to adjust imports. This language telegraphs the possibility of tariff rate adjustments—either increases or extensions to new categories—based on negotiation outcomes. Boards should not assume that the tariff structure announced on April 2 is permanent.
Conclusion: The Governance Framework for Strategic Response
The Section 232 pharmaceutical tariff proclamation creates a defined decision window with specific pathways to tariff mitigation and explicit governance costs. For boards of pharmaceutical and biotech companies, the choice is not whether to respond but which response strategy best serves shareholder value: operational restructuring through onshoring with external monitoring obligations, pricing constraint through MFN agreements, or acceptance of tariff exposure. The decision should be made at the board level with full financial impact modeling, scenario analysis for regulatory change, and clear designation of accountability for implementation and compliance. The governance structure—including external auditing of onshoring plans, retroactive enforcement liability, and forward-looking regulatory adjustments—requires board-level oversight comparable to material litigation risk or significant M&A strategy. Boards that delay this decision accept tariff exposure at the effective date. Boards that act now preserve optionality and demonstrate fiduciary diligence in a restructured trade environment.